MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell LymphomaPRNewsWire • 08/17/21
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific ProgramPRNewsWire • 06/09/21
MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating ZandelisibPRNewsWire • 06/07/21
MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual MeetingPRNewsWire • 06/04/21
MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021PRNewsWire • 05/19/21
MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual CongressPRNewsWire • 05/12/21
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 05/06/21
MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical OfficerPRNewsWire • 04/30/21
Analysts Estimate MEI Pharma, Inc. (MEIP) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/29/21
MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. Food and Drug Administration (FDPRNewsWire • 04/13/21
MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant CancersPRNewsWire • 04/10/21
MEI Pharma to Present Study at the American Association for Cancer Research (AACR) Annual Meeting 2021 Demonstrating that Voruciclib Inhibits KRAS Mutant Cancers in Pre-Clinical ModelsPRNewsWire • 03/10/21
MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational HighlightsPRNewsWire • 02/04/21
MEI Pharma, Inc. (MEIP) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 01/28/21
MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline UpdatePRNewsWire • 01/04/21
MEI PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc. - MEIPBusiness Wire • 12/19/20
MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational HighlightsPRNewsWire • 11/10/20
Shareholder Alert: Robbins LLP Reminds Investors MEI Pharma, Inc. (MEIP) Accused of Misleading ShareholdersBusiness Wire • 10/23/20